

1 Cancer Pain in People with Intellectual Disabilities:
2 Systematic Review and Survey of Health Care Professionals

3
4 *Samantha K. Millard, BSc (a), *Nanda C. de Kneegt, Dr (b)

5
6 (a) Institute for Interdisciplinary Studies, Universiteit van Amsterdam (UvA), The Netherlands

7 (b) Department of Clinical Neuropsychology, Vrije Universiteit Amsterdam (VU), The
8 Netherlands

9 *Both authors have contributed equally to the publication
10
11
12
13
14
15
16
17
18
19
20
21

22 Corresponding Author

23 Name: Samantha K. Millard

24 Address: Institute for Interdisciplinary Studies, Science Park 904, PO box 94224, 1090GE,
25 Amsterdam

26 Phone: +44 (0)7902 190 910

27 Email: sammy14millard@gmail.com

28 Address for reprints: Department of Clinical Neuropsychology, VU University, Van der
29 Boechorststraat 7, 1081 BT Amsterdam, the Netherlands

30 Fax: 0031205988971 (belonging to address for reprints)
31

32 Tables: 5

33 Figures: 1

34 References: 82

35 Word count: 4,450
36

37 Disclosures and Acknowledgements

38 This research did not receive a specific grant from funding agencies in the public,
39 commercial, or not-for-profit sectors. The authors have declared no potential conflicts of
40 interest with respect to the research, authorship, and/or publication of this article. Survey data
41 from this article was previously presented by the second author on the 10th October 2018, at
42 the second international symposium on Cancer in Persons with Intellectual Disability in
43 Montpellier, France. The authors would like to acknowledge Daniel Satgé and Martijn van Oijen
44 for their specific expertise, as well as Christian Christiansen for his critical review of the text.
45

1
2
3 Context: Due to life expectancy improvements for people with intellectual disabilities, their risk of
4 developing cancer is increasing. Pain is an inevitable aspect of cancerous diseases. However, as pain
5 experience and expression can be atypical in people with intellectual disabilities, this population is
6 vulnerable to late diagnosis of cancer and under-treatment of cancer pain. Objectives: To investigate
7 what is currently known about cancer pain in people with intellectual disabilities and provide specific
8 recommendations to improve this knowledge. Methods: A systematic review using PubMed, PsycINFO,
9 and CINAHL, and an anonymous online survey of Dutch health care professionals were conducted.
10 Results: From 10146 publications, with *intellectual disabilities* in the title, and *pain* or *cancer* in the title
11 or abstract, 11 articles underwent qualitative synthesis. Discussions within these articles were
12 predominantly unspecific and brief, frequently indicating challenges in symptom presentation,
13 communication, as well as assessment and treatment of cancer pain. The survey received 102 responses.
14 The 63 health care professionals experienced with cancer in people with intellectual disabilities indicated
15 challenges recognising, assessing, and treating their cancer pain. Conclusion: Cancer pain in people with
16 intellectual disabilities is a topic lacking specific and comprehensive research within scientific literature.
17 We suggest this is due to inherent difficulties regarding the complex interplay of comorbidities and
18 communication issues in people with intellectual disabilities.
19

Introduction

1
2
3 Increased life expectancy for people with intellectual disabilities (PWIDs) due to
4 healthcare improvements (1,2,3) has led to new challenges for health services and carers,
5 including increased deaths from age-related conditions, such as cancer (3,4,5). Age has been
6 described as one of the most important determinants of cancer in the general population (6)
7 and in PWIDs (7,8). However, particular levels of intellectual disabilities (IDs) and ID-associated
8 syndromes have been linked with differing cancer profiles (9). For example, there is an
9 increased risk of gall bladder neoplasms in people with severe IDs, potentially due to sedentary
10 lifestyles and/or high levels of medication due to comorbidities (7). There are inequalities in
11 health provision and care of PWIDs who have cancer (9), as caregivers and health care
12 professionals face challenges at all stages of cancer progression, including prevention,
13 screening, detection, diagnosis, treatment, follow-up, and palliative care (9,10,11). Most
14 significantly, late diagnosis has been identified as a key issue precluding effective treatment of
15 cancer in PWIDs, as it results in poorer prognoses and avoidable deaths (9,12). Reviews on
16 cancer in PWIDs suggest that late diagnosis is, in part, due to difficulties regarding the
17 presentation and assessment of pain symptoms (9,15).

18 Despite the significance of pain in this population (e.g. comorbidities leading to multiple
19 painful surgeries: 16,17,18,19,20), pain is under-recognised and under-treated due to
20 communication difficulties, atypical pain expression, and suspected atypical pain experience
21 (21). Firstly, self-report of pain, commonly used to identify and assess pain in the general
22 population, can be difficult for PWIDs due to communication issues (22). As a consequence,
23 symptoms are under-reported and the presence of cancer can be hidden (7,10). Secondly,
24 assessment of pain relies on the interpretation of behaviours and facial expressions, but these
25 behaviours and expressions may manifest atypically in this population. Behavioural pain
26 indicators can be contradictory and situational, as well as highly individual: dependent on
27 factors such as level of IDs, mental age, and learned behaviour (23,24). Thirdly, atypical pain
28 expression may reflect atypical pain experience (e.g., due to congenital or acquired brain
29 damage, genetic syndromes, or psychopathology). Although atypical experience does not
30 necessarily result in reduced sensitivity (25,26,27,28), caregivers may not take symptoms
31 seriously, as it can be difficult to discriminate pain indicators from anxiety, stress, attention
32 seeking, or problem behaviours (23). Cancer may only be suspected when symptoms become
33 observable (e.g. visible tumours or weight loss), at which point it may be too late to employ
34 effective cancer treatment (29). Therefore, greater understanding of pain as a symptom of
35 cancer in PWIDs will become more critical as the population ages and could reduce the number
36 of avoidable deaths due to late diagnosis.

37 As well as indicating presence of cancer, pain persists after diagnosis, either due to
38 cancer treatments, disease progression, or both in combination (30,31). This cancer pain can
39 be acute or chronic: the former is short term, usually less than three months, caused by
40 surgery, dressing changes, or movement; the latter lasts longer than three months, caused by
41 tumour pressure (i.e., on organs, bones, or nerves), chemical release, or nerve changes due to
42 the disease or treatment (32,33,34). Consequently, cancer pain is a highly important
43 consideration at all stages of disease progression (33). However, atypical pain expression and
44 experience, resulting from the complex interplay of comorbidities and communication issues,
45 could hinder effective cancer pain assessment and management in those with IDs (22,23,24).
46 The present article aimed to investigate what is currently known about cancer pain in PWIDs
47 and provide recommendations to improve this knowledge. Greater understanding would aid
48 earlier diagnoses as well as improve pain assessment and management during cancer

1 treatment and progression, ultimately improving quality of life for PWIDs who have cancer.
2 Due to the clinical relevance of this investigation, two avenues of research were used: a
3 systematic review of scientific literature and a survey of health care professionals.

4 5 **Method**

6 7 **Systematic Review**

8 **Searching.**

9 A systematic search was first conducted in PubMed, PsychINFO, and CINAHL for articles
10 from the last 20 years containing three terms in the title: intellectual disabilities, cancer, and
11 pain. The search did not yield any articles with all three terms, for this reason, 'IDs and pain'
12 and 'IDs and cancer' were independently searched using the inclusion criteria described in
13 Table 1. All papers were required to have a title including 'intellectual disabilities' and either
14 'pain' or 'cancer', and the third search term was required in the abstract or the main text when
15 no abstract was available. The search strategy used for PubMed is illustrated below.

16 17 1. IDs and Pain

18 ((intellectual disabilit*) OR (down* syndrome) OR (mental* retard*))
19 AND (pain* OR discomfort)

20 2. IDs and Cancer

21 ((intellectual disabilit*) OR (down* syndrome) OR (mental* retard*))
22 AND (cancer*)

23
24
25 According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
26 (DSM-5), *intellectual disabilities* (IDs) are disorders involving both intellectual and adaptive
27 functioning deficits in practical, social, or conceptual domains, with an onset during the
28 developmental period (35). Inclusion of *mental retardation* as a search term in the present
29 systematic review improved the search for relevant articles, due to the frequency of its use
30 before the US federal stature (36). *Down syndrome* was included as a search term as it is the
31 most prevalent ID-associated syndrome (37,38). Including other prevalent ID-associated
32 syndromes (e.g. Fragile X syndrome) and conditions (e.g., learning disabilities, dyslexia, autism)
33 as search terms did not improve outcomes, but these were still considered as inclusion criteria
34 (Table 1). The term *cancer* was used in PubMed and CINAHL searches (39), and the terms
35 *leukemia*, *leukaemia*, and *carcinoma* were additionally used in the PsychINFO search. Cancer
36 *pain* is heterogeneous (32,34,40,42) and the search terms *pain* and *discomfort* were used to
37 encompass all varieties.

38
39 Figure 1 displays a flow diagram summarising the systematic search results according to
40 PRISMA guidelines (43). In PubMed, PsychINFO, and CINAHL, the search for 'IDs and pain', and
41 for 'IDs and cancer', found 2011 and 6819 titles, 556 and 92 titles, and 366 and 302 titles,
42 respectively.

43
44 As all the included articles were case reports, quality assessment was conducted using
45 two methods to specifically assess case report quality (44) and allow generalisation and
46 comparison using a tool for appraising heterogeneous literature (45). Both authors of the
47 present paper rated the criteria independently, after which consensus was reached via
48 discussion. Note that quality appraisal of the general article was conducted, rather than

1 specifically appraising the quality of pain reporting. Furthermore, quality appraisal did not
2 determine exclusion of relevant articles, as ratings only indicate the quality of each case report
3 (46).

4 Narrative summary was the most appropriate way to synthesise the information from
5 the case reports (48). Sections of text were identified where pain was mentioned in relation to
6 cancer in PWIDs. Using a 'describe-compare-relate' approach, the first author (SKM) then
7 identified the predominant themes (49) within these extracts to integrate the information and
8 assess how cancer pain in PWIDs is discussed within the literature. Specifically, the
9 characteristics and boundaries of each possible theme were *described*, differences in these
10 themes across varying demographic groups and contexts were *compared* (i.e., what levels and
11 types of IDs, or types of cancer were common within the theme?), and themes were *related* to
12 those already identified (49). No disagreement was found with the second author (NDK). If an
13 article contained a literature review and case report, only the case report underwent appraisal
14 and synthesis.

15

16 **Survey of health care professionals**

17 **Participants, design, and materials.**

18 Data were gathered anonymously via a web-based survey (Qualtrics, Provo, UT) for
19 Dutch health care professionals to explore cancer pain in PWIDs, written in Dutch by the
20 second author (NDK). Besides relevant characteristics to describe the respondents (i.e.
21 profession and experience with cancer pain in PWIDs), survey questions were designed to
22 investigate pain at different stages of cancer progression (e.g, diagnosis, treatment) as well as
23 investigate challenges faced and solutions suggested by health care professionals.

24 The survey was sent to the formal contact person (i.e. secretary) of Dutch associations
25 for the following occupations: physicians for PWIDs, behavioural specialists for PWIDs, dentists
26 for PWIDs, nurses and nursing specialists, oncologists, disabled care, and palliative care.
27 Additionally, the survey link was sent to an online platform for Dutch healthcare practitioners
28 working with PWIDs, to the second author's (NDK) professional contacts working in care
29 centres for IDs, a centre for special dental care, general physicians, and was also displayed on
30 the second author's (NDK) LinkedIn profile. The survey was open between May and September
31 2018. Cross-sectional descriptive data were produced and analysed qualitatively due to the
32 exploratory nature of this investigation.

33

34

34 **Results**

35 **Systematic Review**

36 The present systematic review revealed 11 articles that addressed cancer pain in
37 PWIDs, either in the abstract or main text when no abstract was available. The included
38 publications were all case reports of PWIDs who had cancer
39 (15,50,51,52,53,54,55,56,57,58,59).

40 Using the heterogeneous literature tool (45), percentage quality ranged from 62.5-
41 84.4%. Using the case report tool (44) a 'Yes' response to six or more of the eight quality
42 questions was confirmed for nine of the articles, with one article only confirming four (52) and
43 another five (15) of the questions (Table 2).

44 Most case reports involved adults (9/11), with a mean age of 36 years (SD = 13.56;
45 range = 23-66). The remaining two case reports involved children (i.e. younger than 18 years),
46 with one diagnosed with cancer twice, at the ages of 3 and 6, and a 17 year old. Most of the
47 case reports did not specify the patients' level of IDs (7/11) but commonly involved individuals
48 with Down syndrome (5/11). The remaining articles reported different ID-associated

1 syndromes, stated that the IDs resulted from brain damage caused by a varicella encephalitis
2 virus, or did not specify a cause. Most articles involved various forms of carcinoma (5/11) and
3 leukaemia (2/11); the remaining articles discussed a spinal tumour, thyroid lymphoma, lung
4 cancer, and a case of pericardial mesothelioma (i.e. a rare heart tissue cancer). To summarise,
5 most articles described cancer pain resulting from carcinomas in adults with IDs, especially
6 Down syndrome, often with an unspecified level of IDs.

7 **Cancer pain description themes**

8 From the articles reviewed, three main themes regarding cancer pain in PWIDs were
9 identified. Table 3 shows the characteristics of the 11 accepted articles, with quotations of the
10 exact pain descriptions (for a summary of patient characteristics within each theme, see Online
11 Table 1).

12 **Cancer pain in symptom presentation.** Articles were included in the *cancer pain in*
13 *symptom presentation* category if a patient presented at, or was admitted to, hospital due to
14 pain, or if pain was the revealing symptom of cancer. The majority of the reviewed articles
15 described pain at symptom presentation (9/11). Of these, the pain was usually in adults (7/9)
16 with an unspecified level of IDs (7/9) and Down syndrome (5/9), who were later diagnosed
17 with a variety of cancers.

18 The majority of case reports were not specific about pain at presentation, with two
19 reports merely describing pain location (53,54,59). Other case reports additionally described
20 pain duration: 24 hours (50,57), two weeks (52), 2-3 months (56), or 4-5 months (51,55).
21 Indicating that several individuals had been in pain for weeks or months before presenting at
22 hospital with pain. Of the six articles that were either unspecific regarding pain duration or
23 reported pain durations of two weeks or more, four passed away (52,54,55,56), with cancer
24 only diagnosed at autopsy in two cases (52,54). Kaako and Kolade's article (55) was the only
25 report that contained greater detail on cancer pain at presentation (Table 3). Details of lower
26 back pain in a 25-year-old male with an unspecified level and cause of IDs were described in
27 depth, including the consistency and intensity of pain over the four months prior to
28 presentation. It was not stated exactly how this level of detail was attained. A Large Cell
29 Neuroendocrine Carcinoma (LCNEC) of the lung in the advanced stage was discovered, with
30 metastasis to the spine causing lower back pain. This late diagnosis resulted in immediate
31 admittance to palliative care, and was related to caregivers not acting on pain symptoms soon
32 enough. The authors discuss the importance of recognising and taking signals of pain seriously
33 in PWIDs (55).

34 **Cancer pain communication.** The *cancer pain communication* category included five
35 articles (5/11) that describe how the patient expressed pain (i.e. with behavioural or verbal
36 signals) or describing difficulties in pain communication. The pain was usually in adults (4/5)
37 with an unspecified (3/5) or severe (2/5) level of IDs, with unspecified causes of IDs (2/5) or ID-
38 associated syndromes (3/5), and who were diagnosed with a carcinomas (4/5) or lung cancer.

39 Three articles, all of which did not state level of IDs, described the patients' pain
40 behaviour signals, such as body position, impaired movement, and responses to examination
41 (50,55,57). Gil and colleagues (57) stated that the patient showed "symptoms of pain" when
42 pressure was applied during examination, without describing what these symptoms were (p.
43 1). Two other case reports described difficulties in the communication of pain signals in people
44 with severe levels of IDs (15,58), with one also stating that this contributed to late diagnosis
45 and immediate admittance to palliative care (15).

46 **Cancer pain assessment and treatment.** Lastly, articles in the *cancer pain assessment*
47 *and treatment* category described how pain changed during cancer treatment (e.g. increased
48 or decreased), or described how pain was assessed or treated (i.e. which measurement tools

1 and medications were used). Two articles described pain assessment and treatment (2/11),
2 both in adults with severe levels but unspecified causes of IDs, who were diagnosed with lung
3 cancer and oral cancer.

4 Both articles also featured in the cancer pain communication category, demonstrating
5 overlap between these themes when an individual has severe levels of IDs and thus
6 communication issues. In 2013, Satgé and colleagues (58) described the necessity of
7 developing an individualised pain rating scale due to the patient's poor communication, but did
8 not state whether this was effective or what pain treatments were used. In 2008, Tuffrey-
9 Wijne, Curfs, and Hollins (15) stated that morphine was used to control and treat pain in a
10 palliative care patient, whilst also describing difficulties experienced by caregivers in
11 administering this treatment due to the patient's poor communication (Table 3).

12 **Survey of Health Care Professionals**

13 **Sample characteristics.**

14 In total, 63 of the 102 health care professionals that responded to the online survey
15 had some experience with cancer in PWIDs (61.8%), of which the most common occupation
16 was a physician for PWIDs (42.9%, see Online Table 2). These 63 respondents then answered a
17 series of cancer pain-related questions. When questions permitted multiple answers, the
18 percentage of the 63 professionals who responded affirmatively to each answer is given.

19 **Cancer pain experience.**

20 According to respondents, pain is the symptom that ultimately leads to the diagnosis of
21 cancer in 36.6% of cases (SD = 29.2%, range = 0-100%). Also, 34.2% of respondents believed
22 that organ cancers (e.g., lung, intestine, liver) were the most painful forms of cancer for PWIDs.
23 However, another frequent response (31.8%) was that they did not have enough experience to
24 make a judgement. Several respondents indicated that cancer pain does not differ from other
25 forms of pain in PWIDs (30.2%), while others suggested it was either more (19.1%) or less
26 severe (20.6%) than other forms of pain.

27 Fifteen out of 63 respondents stated that they could not compare cancer pain in people
28 with and without IDs due to lacking experience with both groups (23.8%). Other respondents
29 stated that cancer pain seems less severe in PWIDs (20.6%). However, notably ten respondents
30 wrote that communication and signalling of cancer pain was more difficult or different in those
31 with IDs compared to those without. A further eight wrote that assessment of cancer pain was
32 more difficult, and six wrote that cancer pain was experienced differently in PWIDs compared
33 to those without.

34 **Cancer pain assessment and treatment.**

35 Most professionals stated that observations made by themselves or other health care
36 professionals usually identified cancer pain in PWIDs (90.5%). Observations of behaviour
37 changes by family (55.6%) and self-reports by the patient (31.8%) were the next most frequent
38 recognition methods used. As displayed in Table 4, 54 professionals usually measured cancer
39 pain by knowing the patient's individual pain behaviours (85.7%), and said it was effective
40 (69%).

41 Most respondents reported use of strong opiates (85.7%) and paracetamol (81%; Table
42 4). Respondents usually employed strong opiates during palliative cancer care (70.4%) and
43 stated that they were generally effective in relieving cancer pain in PWIDs (87%). In contrast,
44 paracetamol was typically used in the early phases of cancer (80.4%), with 51% stating the
45 treatment was effective. Several respondents commented that they use a variety of drugs or
46 therapies to treat cancer pain in PWIDs, including alternative therapies such as massage,
47 music, physiotherapy, and distraction.
48

1 knowledge on the experience and expression of pain in PWIDs. Clear assessment and thus
2 clear descriptions of pain are then hindered.

3 Whether the limited amount of research and brief descriptions of cancer pain in the
4 systematic review are due to insufficient levels of knowledge or merely insufficient levels of
5 focus on this topic is unclear, as both remain plausible. In either case, understanding gained
6 from the literature is limited and issues relating to this topic will continue.

7

8 **Assessment of Cancer Pain**

9 Eight of the professionals in the survey suspected that apparent reduced pain severity
10 in PWIDs might be due to difficulties in communication and assessment of pain. Some
11 respondents commented on their own low knowledge of behavioural pain signals in PWIDs
12 (see Online Table 4: clinical situation 7). However, knowing the patient and their individual
13 behaviours was reported to be most helpful for recognising and assessing cancer pain in
14 PWIDs, which corresponds to previous literature (8,67). Still, the present investigation
15 indicates gaps in literature and clinical practice regarding effective recognition and assessment
16 of cancer pain in PWIDs. Difficulties assessing cancer pain is a prominent issue, leading to
17 serious consequences including the late diagnosis of cancer and difficulties with cancer pain
18 treatment.

19 **Late diagnosis of cancer.**

20 Cancer is less treatable if diagnosed at a late stage, leading to poorer prognosis (9,12).
21 The present literature review (15,52,54,55,58) and survey support suggestions from previous
22 literature (7,9,10,22,23,24,68) that late diagnosis of cancer in PWIDs is a significant issue, due
23 in part to difficulties regarding the assessment of pain symptoms, meaning that symptoms are
24 under-reported and the presence of cancer can be hidden. Multiple case report patients had
25 pain for several weeks or months before they presented at hospital (51,52,55,56). Three
26 individuals had extensive metastasis (15,55,56) and cancer was only discovered during autopsy
27 in two other individuals (52,54), exhibiting the severity of late diagnosis. A possible cause could
28 be communication issues (15) and caregivers not recognising or acting on the pain soon
29 enough (55). This indicates overlap between *cancer pain communication* and *cancer pain at*
30 *presentation* categories. Survey respondents stated that diagnosis using pain signalling is not
31 straight forward, as communication, recognition, and assessment of pain were challenges they
32 faced.

33 **Under treatment of cancer pain.**

34 We observed a general lack of focus on reporting the treatment of cancer pain within
35 case reports. Excluding the surgical removal of tumours, only one article stated how cancer
36 pain was treated (i.e. with morphine: 15). However, within this, caregivers did not know when
37 to give the patient extra analgesia, as the patient was unable to clearly indicate their pain.
38 Difficulties treating cancer pain in PWIDs can also be seen in the survey results (Online Table
39 4).

40 In line with general population guidelines, the use of cancer pain treatments by survey
41 respondents varied across the different phases of cancer, for example strong opioids at late
42 stages of cancer (33). A few respondents use a variety of drugs or therapies to treat cancer
43 pain in PWIDs, including alternative therapies. Recognising the importance of combined
44 therapies is critical due to potentially altered analgesic effectiveness and drug-to-drug
45 interactions resulting from comorbidities in PWIDs (62). Authors of the reviewed case reports
46 may have known more about cancer pain treatment in PWIDs, but did not report it as this was
47 not the focus of their article.

1 Treatment of cancer pain in PWIDs was identified as a challenge experienced by over
2 60% of survey respondents. Issues of patient comorbidities, cooperation and understanding of
3 treatments, as well as evaluation of treatment effectiveness were stated (Online Table 4,
4 clinical situation 12 is a poignant example). Respondents' judgement of the effectiveness of
5 cancer pain treatments in PWIDs in the present survey results should be viewed with caution
6 due to inherent difficulties in pain assessment highlighted by the respondents themselves.
7 Taken together, health care professionals appeared to know about appropriate cancer pain
8 treatments and management, but are also aware of knowledge gaps specific to PWIDs
9 challenging their practice (i.e. mainly pain assessment). A major knowledge gap highlighted by
10 both the literature review and survey was that no specific cancer pain management guidelines
11 for PWIDs exist.

12 13 **Limitations**

14 A crucial limitation of the present investigation is that the survey results are opinions
15 from only 63 Dutch professionals and therefore cannot be generalised to how cancer pain is
16 recognised, measured, and treated worldwide. Yet, although low causality and generalisability
17 are limitations, they clearly highlight necessity for further investigation into this topic. There
18 are serious consequences to having low focus and knowledge on this topic, i.e. late diagnosis
19 of cancer and under treatment of cancer pain. Thus, it is important to increase focus and
20 knowledge on this topic in order to improve quality of life for PWIDs who have cancer. Several
21 recommendations are provided below to combat the aforementioned issues.

22 23 **Recommendations**

24 Comprehensive cancer pain guidelines specifically for PWIDs are beyond the scope of
25 the present article. However, Table 5 contains recommendations from surveyed health care
26 professionals, supported by systematic review results and surrounding research, along with
27 suggestions for future research avenues. Future development of guidelines for PWIDs would
28 be valuable, and might also be translatable to dementia due to comparable communication
29 issues and alterations in pain-related neurophysiology (12,33,74).

30 As pain discussions within case reports were largely unspecific and brief, we primarily
31 recommend conducting a single-arm uncontrolled cohort study on cancer pain, following
32 PWIDs and cancer. To differentiate it from a case series, such a study would require a set
33 protocol, inclusion and exclusion criteria, standardised follow up, and reported drop out
34 numbers (80). Building qualitative elements such as interviews into a cohort study would
35 improve understanding of the experience of cancer pain for someone with IDs and cancer, also
36 involving family and caregivers. The viewpoints of PWIDs will aid the development of cancer
37 pain support that is suitable to and considerate of their needs (81,82).

38 39 **Conclusions**

40 The present article intended to investigate what is known about cancer pain in PWIDs
41 within scientific literature and clinical practice. A systematic review found only a limited
42 number of case reports containing unspecific and brief descriptions of cancer pain in PWIDs. A
43 survey of health care professionals indicated challenges in recognition, assessment, and
44 treatment of cancer pain in PWIDs. In combination, the two investigations suggest that there is
45 an insufficient level of knowledge and focus on cancer pain in PWIDs leading to continued
46 difficulties with communication and cooperation, as well as recognition, assessment, and
47 treatment of cancer pain. Expanding knowledge on cancer pain will become increasingly
48 important as more PWIDs live to an age where the risk of cancer increases. Recommendations

1 outlined here would aid earlier diagnosis of cancers in PWIDs as well as improve cancer pain
2 assessment and treatment. This would ultimately increase quality of life for PWIDs who have
3 cancer by reducing unnecessary suffering from pain.

4
5
6

Journal Pre-proof

References

- 1
2
3 An asterisk indicate studies included in the systematic review
4
5 (1) Lauer E, McCallion P. Mortality of People with Intellectual and Developmental Disabilities from
6 Select US State Disability Service Systems and Medical Claims Data. *J Appl Res Intellect Disabil*
7 (Oxford), 2015;28:394–405. <http://doi.org/10.1111/jar.12191>
- 8 (2) Patja K, Iivanainen M, Vesala H, Oksanen H, Ruoppila I. Life expectancy of people with intellectual
9 disability: A 35-year follow-up study. *JIDR (Oxford)* 2000;44(5): 591–599.
10 <https://doi.org/10.1046/j.1365-2788.2000.00280.x>
- 11 (3) Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down’s syndrome in the USA from
12 1983 to 1997: A population-based study. *Lancet*, 2002; 359(9311):1019–1025.
13 [http://doi.org/10.1016/S0140-6736\(02\)08092-3](http://doi.org/10.1016/S0140-6736(02)08092-3)
- 14 (4) Day K, Jancar J. Mental and physical health and ageing in mental handicap: a review. *JIDR (Oxford)*,
15 1994;38(3):241–56. Retrieved November 12th 2018 from:
16 <http://www.ncbi.nlm.nih.gov/pubmed/8061470>
- 17 (5) Evenhuis HM, Hermans H, Hilgenkamp TIM, Bastiaanse LP, Ehteld MA. Frailty and Disability in Older
18 Adults with Intellectual Disabilities : Results from the Healthy Ageing and Intellectual Disability
19 Study. *J Am Geriatr Soc (Baltimore MD)*, 2012;60(5):934–938. <http://doi.org/10.1111/j.1532-5415.2012.03925.x>
- 20
21 (6) Yarbro CH, Wujcik D, Gobel BH. *Cancer Nursing Principles and Practice*, Eighth Edition. Burlington,
22 MA, 2018: Jones & Bartlett Learning.
- 23 (7) Patja K, Eero P, Iivanainen M. Cancer incidence among people with intellectual disability. *JIDR*
24 (Oxford), 2001;45(4):300–307. <http://doi.org/10.1046/j.1365-2788.2001.00322.x>
- 25 (8) Sullivan SG, Hussain R, Threlfall T, Bittles AH. The incidence of cancer in people with intellectual
26 disabilities. *Cancer Causes Control*, (Oxford), 2004;15(10):1021–5. Retrieved September 2018 from
27 <http://www.ncbi.nlm.nih.gov/pubmed/15801486>
- 28 (9) Hogg J, Tuffrey-Wijne I. Cancer and intellectual disability: a review of some key contextual issues. *J*
29 *Appl Res Intellect Disabil (Oxford)*, 2008;21(6):509-518. [https://doi.org/10.1111/j.1468-](https://doi.org/10.1111/j.1468-3148.2008.00422.x)
30 [3148.2008.00422.x](https://doi.org/10.1111/j.1468-3148.2008.00422.x)
- 31 (10) Satgé D, Kempf E, Dubois JB, Nishi M, Trédaniel J. Challenges in Diagnosis and Treatment of
32 Lung Cancer in People with Intellectual Disabilities: Current State of Knowledge. *Lung Cancer*
33 *Int (London)*, 2016; 1–7. <https://doi.org/10.1155/2016/6787648>
- 34 (11) Tuffrey-Wijne I, Hogg J, Curfs L. End-of-life and palliative care for people with intellectual
35 disabilities who have cancer or other life-limiting illness: A review of the literature and available
36 resources *J Appl Res Intellect Disabil (Oxford)*, 2007;20(4):331–344.
37 <http://doi.org/10.1111/j.1468-3148.2006.00350.x>
- 38 (12) Neal RD. Do diagnostic delays in cancer matter? *Br J Cancer (Edinburgh)*, 2009;101: S9–S12.
39 <https://doi.org/10.1038/sj.bjc.6605384>
- 40 (13) Bagan J, Sarrion G, Jimenez Y. Oral cancer: Clinical features. *Oral Oncol (Oxford)*, 2010;46(6):414–
41 417. <http://doi.org/10.1016/j.oraloncology.2010.03.009>
- 42 (14) Teanby S. A literature review into pain assessment at triage in accident and emergency
43 departments. *Accid Emerg Nurs (Edinburgh)*, 2003;11(1):12-17. [https://doi.org/10.1016/S0965-](https://doi.org/10.1016/S0965-2302(02)00132-7)
44 [2302\(02\)00132-7](https://doi.org/10.1016/S0965-2302(02)00132-7)

- 1 (15) * Tuffrey-Wijne I, Curfs L, Hollins S. Providing palliative care to people with intellectual disabilities
2 who have cancer. *Int J Disabil Hum Dev* (London), 2008;7(4):379–384.
3 <http://doi.org/10.1515/IJDHD.2008.7.4.379>
- 4 (16) Baldrige KH, Andrasik F. Pain assessment in people with intellectual or developmental
5 disabilities. *AJN* (New York NY), 2010;110(12):28-35.
6 <https://doi.org/10.1097/01.NAJ.0000391236.68263.90>
- 7 (17) Breau LM, Camfield CS, McGrath PJ, Finley GA. The Incidence of Pain in Children With Severe
8 Cognitive Impairments. *Arch Pediatr Adolesc Med* (Chicago IL), 2003;157(12):1219.
9 <https://doi.org/10.1001/archpedi.157.12.1219>
- 10 (18) Krigger KW. Cerebral Palsy: An Overview. *Am Fam Physician* (Kansas City MO), 2006;73(1):91–100.
11 <http://doi.org/10.1007/s12098-017-2475-1>
- 12 (19) Traci MA, Seekins T, Szalda-petree A, Ravesloot C. Developmental Disabilities: A Preliminary Study.
13 *Ment Retard* (Washington DC), 2002;40(2):119–131. [https://doi.org/10.1352/0047-](https://doi.org/10.1352/0047-6765(2002)040<0119:ASCAAW>2.0.CO;2)
14 [6765\(2002\)040<0119:ASCAAW>2.0.CO;2](https://doi.org/10.1352/0047-6765(2002)040<0119:ASCAAW>2.0.CO;2)
- 15 (20) Walsh M, Morrison TG, McGuire BE. Chronic pain in adults with an intellectual disability:
16 Prevalence, impact, and health service use based on caregiver report. *Pain* (Amsterdam),
17 2011;152(9):1951–1957. <https://doi.org/10.1016/j.pain.2011.02.031>
- 18 (21) McGuire BE, Daly P, Smyth F. Chronic pain in people with an intellectual disability: Under-
19 recognised and under-treated? *JIDR* (Oxford), 2010;54(3):240–245.
20 <https://doi.org/10.1111/j.1365-2788.2010.01254.x>
- 21 (22) Dubois A, Capdevila X, Bringuier S, Pry R. Pain expression in children with an intellectual disability.
22 *Eur J Pain* (London), 2010;14(6):654–660. <https://doi.org/10.1016/j.ejpain.2009.10.013>
- 23 (23) De Knecht NC, Pieper MJC, Lobbezoo F et al. Behavioral pain indicators in people with intellectual
24 disabilities: A systematic review. *J Pain* (Philadelphia PA), 2013;14(9):885–896.
25 <https://doi.org/10.1016/j.jpain.2013.04.016>
- 26 (24) Defrin R, Lotan M, Pick CG. The evaluation of acute pain in individuals with cognitive impairment: A
27 differential effect of the level of impairment. *Pain* (Amsterdam), 2006;124(3):312–320.
28 <http://doi.org/10.1016/j.pain.2006.04.031>
- 29 (25) Devarakonda KM, Lowthian D, Raghavendra T. A case of Rett syndrome with reduced pain
30 sensitivity. *Paediatr Anaesth* (Paris), 2009;19:625–627. [http://doi.org/10.1111/j.1460-](http://doi.org/10.1111/j.1460-9592.2009.03018.x)
31 [9592.2009.03018.x](http://doi.org/10.1111/j.1460-9592.2009.03018.x)
- 32 (26) Symons FJ, Shinde SK, Gilles E. Perspectives on pain and intellectual disability. *JIDR* (Oxford),
33 2008;52(4):275–286. <http://doi.org/10.1111/j.1365-2788.2007.01037.x>
- 34 (27) De Knecht N, Scherder E. Pain in adults with intellectual disabilities. *Pain* (Amsterdam),
35 2011;152(5):971–974. <https://doi.org/10.1016/j.pain.2010.11.001>
- 36 (28) Scherder EJA, Sergeant JA, Swaab DF. Pain processing in dementia and its relation to
37 neuropathology. *Lancet Neurol* (London), 2009; 1(11), 677–686. [http://doi.org/10.1016/S1474-](http://doi.org/10.1016/S1474-4422(03)00556-8)
38 [4422\(03\)00556-8](http://doi.org/10.1016/S1474-4422(03)00556-8)
- 39 (29) Evenhuis HM. Medical aspects of ageing in a population with intellectual disability: III. Mobility,
40 internal conditions and cancer. *JIDR* (Oxford), 1997;41(1):8-18 [http://doi.org/10.1111/j.1365-](http://doi.org/10.1111/j.1365-2788.1997.tb00672.x)
41 [2788.1997.tb00672.x](http://doi.org/10.1111/j.1365-2788.1997.tb00672.x)
- 42 (30) Glare PA, Davies PS, Finlay E et al. Pain in cancer survivors. *J Clin Oncol* (Philadelphia PA),
43 2014;32(16):1739–1747. <http://doi.org/10.1200/JCO.2013.52.4629>

- 1 (31) Van Den Beuken-Van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen
2 DJA. Update on Prevalence of Pain in Patients with Cancer: Systematic Review and Meta-Analysis.
3 J Pain Symptom Manage (New York NY) 2016;51(6):1070–1090.e9.
4 <http://doi.org/10.1016/j.jpainsymman.2015.12.340>
- 5 (32) Doody O, Bailey ME. Interventions in pain management for persons with an intellectual disability.
6 JIDR (Oxford), 2017:1-13. <http://doi.org/10.1177/1744629517708679>
- 7 (33) Fallon M, Giusti R, Aielli F et al. Management of cancer pain in adult patients: ESMO Clinical
8 Practice Guidelines. Ann Oncol (Dordrecht) 2018;29(July):166–191.
9 <http://doi.org/10.1093/annonc/mdy152>
- 10 (34) Faull C, de Caestecker S, Nicholson A, Black F. Handbook of Palliative Care, Third Edition. Hoboken:
11 Wiley-Blackwell, 2012. ISBN: 978-1-118-06559-4
- 12 (35) American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®).
13 Arlington, VA: American Psychiatric Publishing, 2013.
- 14 (36) Salvador-Carulla L, Bertelli M. ‘Mental retardation’ or ‘intellectual disability’: time for a conceptual
15 change. Psychopathology (Basel), 2008;41(1):10-16. <https://doi.org/10.1159/000109950>
- 16 (37) Centers for Disease Control and Prevention (CDC). Down syndrome prevalence at birth--United
17 States, 1983-1990. MMWR Morb Mortal Wkly Rep (Atlanta GA), 1994;43(33):617. Retrieved
18 November 12th 2018 from: <https://www.cdc.gov/mmwr/preview/mmwrhtml/00032401.htm>
- 19 (38) Cocchi G, Gualdi S, Bower C, et al. International trends of Down syndrome 1993–2004: births in
20 relation to maternal age and terminations of pregnancies. Birth Defects Res A Clin Mol Teratol
21 (US), 2010;88(6):474-479. <https://doi.org/10.1002/bdra.20666>
- 22 (39) “Cancer.” *Farlex Partner Medical Dictionary*. 2012. Retrieved September 21st 2018 from:
23 <https://medical-dictionary.thefreedictionary.com/cancer>
- 24 (40) Colman AM. A Dictionary of Psychology. Oxford University Press, USA, 2015. ISBN: 978-0-19-
25 965768-1
- 26 (41) Noble M, Tregear SJ, Treadwell JR, Schoelles K. Long-term opioid therapy for chronic noncancer
27 pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage (New
28 York NY), 2008;35(2):214-228. <https://doi.org/10.1016/j.jpainsymman.2007.03.015>
- 29 (42) Boddice R. PAIN: A Very Short Introduction. New York: Oxford University Press, 2017.
- 30 (43) Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and
31 meta-analyses: the PRISMA statement. Ann Intern Med (Philadelphia PA), 2009;151(4):264-269.
32 <https://doi.org/10.1371/journal.pmed.1000097>
- 33 (44) Moola S, Munn Z, Tufanaru C et al. Chapter 7: Systematic reviews of etiology and risk. In:
34 Aromataris E, Munn Z (Editors). *Joanna Briggs Institute Reviewer's Manual*. The Joanna Briggs
35 Institute, 2017. Available from <https://reviewersmanual.joannabriggs.org/>
- 36 (45) Hawker S, Payne S, Kerr C, Hardey M, Powell J. Appraising the evidence: reviewing disparate data
37 systematically. Qual Health Res (California CA). 2002;12(9):1284-99.
38 <https://doi.org/10.1177/1049732302238251>
- 39 (46) Walsh D, Downe S. Appraising the quality of qualitative research. Midwifery (New York NY).
40 2006;22(2):108-19. <https://doi.org/10.1016/j.midw.2005.05.004>
- 41 (47) Hong QN, Pluye P, Fàbregues S et al. Mixed methods appraisal tool (MMAT), version 2018. IC
42 Canadian Intellectual Property Office, Canada. 2018. Available from
43 [http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_2018_crit](http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf)
44 [eria-manual_2018-08-01_ENG.pdf](http://mixedmethodsappraisaltoolpublic.pbworks.com/w/file/attach/127916259/MMAT_2018_criteria-manual_2018-08-01_ENG.pdf)

- 1 (48) Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series
2 and case reports. *BMJ Evid Based Med* (London) 2018;23(2):60-3.
3 <http://dx.doi.org/10.1136/bmjebm-2017-110853>
- 4 (49) Bazeley P. Analysing qualitative data: More than 'identifying themes'. *Malays j res* (Online). 2009
5 Jan;2(2):6-22. <http://doi.org/10.1080/09613218.2017.1366138>
- 6 (50) * Koorey D. Appendiceal carcinoma complicating adenomatous polyposis in a young woman with a
7 de novo constitutional reciprocal translocation t(5;8)(q22;p23.1). *J Med Genet*
8 (London), 2000;37(1):71–75. Retrieved September 2018 from
9 <http://jmg.bmj.com/cgi/doi/10.1136/jmg.37.1.71>
10 1.71
- 11 (51) * Yang CY, Juang SS, Chuang SS, Chou CW, Lin MB. Down's syndrome with mucosa-associated
12 lymphoid tissue, thyroid lymphoma and cerebral infarction. *Zhonghua yi xue za zhi= Chinese*
13 *medical journal; Free China ed*, 2000;63(3):234-239. ISSN: 0578-1337
- 14 (52) * Sharaf El-Dean MZ, Bakshi NA, Giraldo AA. Pathologic quiz case: A patient with down syndrome
15 presenting with "Idiopathic" pericarditis. *Arch Pathol Lab Med* (Northfield
16 IL), 2004;128(August):107–108. ISSN: 0003-9985
- 17 (53) * Hellebostad M, Carpenter E, Hasle H, Mitchell C, Vyas P. GATA1 mutation analysis demonstrates
18 two distinct primary leukemias in a child with Down syndrome; implications for leukemogenesis. *J*
19 *Pediatr Hematol Oncol* (New York NY), 2005;27(7):408–409.
20 <https://doi.org/10.1097/01.mph.0000172223.04694.c4>
- 21 (54) * Hjorth SV, Vainer B, Petersen BL, Larsen FS, Hasle H. Acute lymphoblastic leukemia with
22 Philadelphia chromosome in a 39-year-old woman with Down syndrome presenting as meningitis
23 and fulminant liver failure. *Leuk Res* (Oxford), 2010;34(11):297–299.
24 <https://doi.org/10.1016/j.leukres.2010.06.007>
- 25 (55) * Kaako A, Kolade VO. Back pain and mental retardation. *Tenn Med* (Nashville TN), 2010;103(8):37-
26 8. ISSN: 1088-6222
- 27 (56) * Purvey S, Hanna M, Shaib W, Saif MW. A case of Down syndrome who developed pancreatic
28 cancer: a case report and review of literature. *JOP* (Genova), 2010;11(3):285-287. Retrieved
29 September 2018 from:
30 <http://www.bollettinofilosofico.unina.it/index.php/jop/article/view/3833/4275>
- 31 (57) * Gil AT, Brett A, Cordinhã C, Gomes C. Bilateral renal cell carcinoma in a paediatric patient with
32 tuberous sclerosis complex. *BMJ* (Case Reports) (London), 2013:10–12.
33 <https://doi.org/10.1136/bcr-2013-010015>
- 34 (58) * Satgé D, Clémenson P, Nishi M et al. A mucoepidermoid carcinoma in a young man with
35 intellectual disability: Review of oral cancer in people with intellectual disability. *Oral Surg Oral*
36 *Med Oral Pathol Oral Radiol* (Philadelphia PA), 2013;115(5):e22–e27.
37 <https://doi.org/10.1016/j.oooo.2012.10.010>
- 38 (59) * Roma D, Palma P, Capolino R et al. Spinal ependymoma in a patient with Kabuki syndrome: A
39 case report. *BMC Med Genet* (London), 2015;16(1):1–4. [https://doi.org/10.1186/s12881-015-](https://doi.org/10.1186/s12881-015-0228-4)
40 0228-4
- 41 (60) Chou R, Waseem A, Snow V et al. Clinical Guidelines Diagnosis and Treatment of Low Back Pain : A
42 Joint Clinical Practice Guideline from the American College of Physicians and the American. *Ann*
43 *Intern Med*, Philadelphia PA), 2007;147(7):478–491. [http://doi.org/10.7326/0003-4819-147-7-](http://doi.org/10.7326/0003-4819-147-7-200710020-00006)
44 200710020-00006
- 45 (61) Zacharias J, Nicholson AG, Ladas GP, Goldstraw P. Large cell neuroendocrine carcinoma and large
46 cell carcinomas with neuroendocrine morphology of the lung: Prognosis after complete resection

- 1 and systematic nodal dissection. *Ann Thorac Surg* (New York NY), 2003;75(2):348–352.
2 [http://doi.org/10.1016/S0003-4975\(02\)04118-](http://doi.org/10.1016/S0003-4975(02)04118-)
- 3 (62) Bekkema N, Veer A, de Hertogh CM, Francke AL. Palliatieve zorg voor mensen met een
4 verstandelijke beperking. *Utrecht*, 2011:5–7. [https://doi.org/10.1016/B978-1-78242-381-2.00010-](https://doi.org/10.1016/B978-1-78242-381-2.00010-9)
5 9
- 6 (63) “Carcinoma.” *Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health,*
7 *Seventh Edition*. 2003. Retrieved October 19th 2018 from: [https://medical-](https://medical-dictionary.thefreedictionary.com/carcinoma)
8 [dictionary.thefreedictionary.com/carcinoma](https://medical-dictionary.thefreedictionary.com/carcinoma)
- 9 (64) “Carcinoma.” *Mosby's Medical Dictionary, 8th edition*. 2009. Retrieved October 19th 2018 from:
10 <https://medical-dictionary.thefreedictionary.com/carcinoma>
- 11 (65) “Metastatic cancer.” National Cancer Institute. 2017. Retrieved October 19th 2018 from:
12 <https://www.cancer.gov/types/metastatic-cancer>
- 13 (66) Beacroft M, Dodd K. Pain in people with learning disabilities in residential settings - the need for
14 change. *Br J Learn Disabil* (Avon UK), 2010;38(3):201–209. [http://doi.org/10.1111/j.1468-](http://doi.org/10.1111/j.1468-3156.2009.00593.x)
15 3156.2009.00593.x
- 16 (67) De Knecht NC. Pain in older adults with intellectual disabilities. In Pickering, G., Zwakhalen, S.,
17 Kaasalainen, S. (Eds.). *Pain management in older adults: a nursing perspective*. New York: Springer
18 International Publishing, 2018.
- 19 (69) Hearn J, Higginson I. Epidemiology of cancer pain. In Bruera, E. D., Portenoy, R. K. (Eds). *Cancer*
20 *Pain: Assessment and Management*. Cambridge UK: Cambridge University Press, 2003.
- 21 (70) Downie A, Williams CM, Henschke N et al. Red flags to screen for malignancy and fracture in
22 patients with low back pain. *British Journal of Sports Medicine*, 2014;48(20):1518.
23 <http://doi.org/10.1136/bjsports-2014-f7095rep>
- 24 (71) NHS England. Delivering high quality end of life care for people who have a learning disability.
25 Resources and tips for commissioners, service providers and health and social care staff. 2017:1-
26 57. Retrieved November 2018 from: [https://www.england.nhs.uk/publication/delivering-high-](https://www.england.nhs.uk/publication/delivering-high-quality-end-of-life-care-for-people-who-have-a-learning-disability/)
27 [quality-end-of-life-care-for-people-who-have-a-learning-disability/](https://www.england.nhs.uk/publication/delivering-high-quality-end-of-life-care-for-people-who-have-a-learning-disability/)
- 28 (72) Tuffrey-Wijne I, McEnhill L. Communication difficulties and intellectual disability in end-of-life care.
29 *Int J Palliat Nurs* (London). 2008 Apr;14(4):189-94. <https://doi.org/10.12968/ijpn.2008.14.4.29133>
- 30 (73) Marsden S. Piloting the Anticipatory Care Calendar. 2018. Retrieved November 2018 from:
31 <https://slideplayer.com/slide/9518285/>
- 32 (74) Herr K, Coyne PJ, Key T et al. Pain Assessment in the Nonverbal Patient: Position Statement with
33 Clinical Practice Recommendations. *Pain Manag Nurs* (Philadelphia PA), 2006;7(2):44–52.
34 <http://doi.org/10.1016/j.pmn.2006.02.003>
- 35 (75) Solodiuk JC, Scott-Sutherland J, Meyers M et al. Validation of the Individualized Numeric Rating
36 Scale (INRS): A pain assessment tool for nonverbal children with intellectual disability. *Pain*
37 (Amsterdam), 2010;150(2):231–236. <http://doi.org/10.1016/j.pain.2010.03.016>
- 38 (76) McCallion P, McCarron M, Fahey-McCarthy E, Connaire K. Meeting the end of life needs of older
39 adults with intellectual disabilities. In: Chang E, Johnson A, eds. *Contemporary and Innovative*
40 *Practice in Palliative Care, Croatia*: InTech, 2012:255–270. <http://doi.org/10.5772/50570>
- 41 (77) Ali A, Hassiotis A. Illness in people with intellectual disabilities is common, underdiagnosed, and
42 poorly managed. *BMJ* (London), 2008;336(7644):570–571.
43 <http://doi.org/10.1136/bmj.39506.386759.80>

- 1 (78) Glover G, Williams R, Heslop P, Oyinlola J, Grey J. Mortality in people with intellectual disabilities in
2 England. *J Appl Res Intellect Disabil (Oxford)*, 2017;61(1):62–74. <http://doi.org/10.1111/jir.12314>
- 3 (79) Oberlander T, Symons F. *Pain in children & adults with developmental disabilities*. Baltimore, MD:
4 Paul H. Brooks Publishing Co, 2006.
- 5 (80) Dekkers OM, Egger M, Altman DG. Distinguishing case series from cohort studies. *Ann Intern Med*
6 (Philadelphia PA), 2012;156(1 Part 1):37-74. [http://doi.org/10.7326/0003-4819-156-1-201201030-](http://doi.org/10.7326/0003-4819-156-1-201201030-00006)
7 00006
- 8 (81) Tuffrey-Wijne I, Davies J. This is my story: I've got cancer. 'The Veronica Project': an ethnographic
9 study of the experience of people with learning disabilities who have cancer. *Br J Learn Disabil*
10 (Avon), 2007;35(1):7-11. <http://doi.org/10.1111/j.1468-3156.2006.00421.x>
- 11 (82) Tuffrey -Wijne I, Bernal J, Hollins S. Doing research on people with learning disabilities, cancer and
12 dying: ethics, possibilities and pitfalls. *Br J Learn Disabil (Avon)*, 2008;36(3):185-190.
13 <http://doi.org/10.1111/j.1468-3156.2008.00519.x>

14

1 Figure Legend

2

3 *Figure 1.*

4 Flow diagram (PRISMA) displaying the systematic selection process following database
5 searches in PubMed, PsychINFO, and CINAHL for intellectual disabilities (IDs) and cancer or
6 pain. Selection phases include identification, screening, eligibility, and final inclusion, utilising
7 the inclusion and exclusion criteria in Table 1.

8

9

10 Supplementary Digital Content list

11

12

13 Online Table 1.docx

14 Online Table 2.docx

15 Online Table 3.docx

16 Online Table 4.docx

17

18

19

20

Journal Pre-proof

Table 1

Inclusion and exclusion criteria for systematic literature search.

Inclusion criteria	Exclusion criteria
Articles (all study types [e.g., cross-sectional, case-control, case series])	Literature reviews, published commentaries and letters
Publication year 1998-2018	Publication year older than 1998
Written in English	Written in a language other than English
Human studies	Animal studies
Intellectual disabilities in title and abstract (synonyms include, developmental disabilities [if also having intellectual disabilities] and genetic syndromes [e.g., Fragile X syndrome, Rett syndrome, Tuberous Sclerosis Complex])	Other developmental or neurological conditions (e.g., autism, cerebral palsy, or epilepsy), or learning disabilities (e.g., dyslexia or dyspraxia) without also having intellectual disabilities
Pain or discomfort in title, or in abstract if title contained cancer and intellectual disabilities (synonyms include, painful and acute)	Congenital insensitivity to pain, congenital sensory neuropathy, or hereditary sensory and autonomic neuropathy
This pain or discomfort could be identified as a symptom of cancer, resulting from cancer treatment [e.g., radiotherapy, chemotherapy, or surgery], or during palliative care of cancer patients	Description of distress in title or abstract, without also having pain or discomfort. (Distress may only relate to fear or anxiety, which was not the focus of the present article) Pain or discomfort during cancer screening procedures (e.g. mammography) without cancer being diagnosed
Cancer in title, or in abstract if title contained pain and intellectual disabilities (all forms of cancer were included [e.g., malignant tumours, leukaemia, carcinoma])	Tumours found to be benign Other diseases or health issues (e.g., arthritis, gastro-oesophageal reflux disease) without also having cancer

Journal Pre-proof

Table 2

Subscores, total scores, and percentage of overall quality for all included literature review articles using the heterogeneous literature tool (45) and Joanna Briggs Institute (JBI) case study tool (44).

Criteria and references	Koorey et al, 2000 (50)	Yang, Juang, and Chou, 2000 (51)	Sharaf El-Dean, Bakshi, and Giraldo, 2004 (52)	Hellebostad, Carpenter, Hasle, Mitchell, and Vyas, 2005 (53)	Tuffrey-Wijne, Curfs, and Hollins, 2008 (15)	Hjorth, Vainer, Petersen, and Hasle, 2010 (54)	Kaako and Kolade, 2010 (55)	Purvey, Hanna, Shaib, and Saif, 2010 (56)	Gil, Brett, Cordinhã, and Gomes, 2013 (57)	Satgé et al., 2013 (58)	Roma et al., 2015 (59)
Heterogeneous literature quality tool (4 = Good, 3 = Fair, 2 = Poor, 1 = Very poor)											
Abstract and title	1	4	1	1	4	1	4	1	4	4	4
Introduction and aims	2	3	3	3	3	3	2	3	3	3	3
Method and data	4	4	4	4	3	4	4	4	4	4	4
Sampling	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Data analysis	4	n/a	n/a	4	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Ethics and bias	2	2	2	3	3	2	2	3	2	4	4
Findings/results	4	4	4	4	4	4	4	4	4	4	4
Transferability/generalizability	4	4	4	4	3	4	4	4	4	4	4
Implications and usefulness	2	3	2	4	4	3	3	4	3	4	4
Quality rating:	23	24	20	27	24	21	23	23	24	27	27
Total possible rating:	36	32	32	36	32	32	32	32	32	32	32
Percentage quality:	63.89%	75%	62.5%	75%	75%	65.63%	71.88%	71.88%	75%	84.38%	84.38%

Table 3

Summary of study characteristics, arranged by date with direct quotes of pain descriptions.

Journal Pre-proof

Authors	Type of study	Patient	Form of cancer	Form of pain	Direct quote containing discussion of cancer pain in people with IDs	Further details (diagnosis, treatment, and outcomes)
---------	---------------	---------	----------------	--------------	--	--

Journal Pre-proof

Koorey, Basha, Tomaras, Freiman, Robson, and Smith, 2000 (50)	Case report with genetic analysis	Adult female 26 years	Appendiceal carcinoma (i.e. a cancer that began in the tissue lining the appendix)	Right iliac fossa pain (i.e., pain in the hip bone)	“She presented acutely at 26 years of age with a 24 hour history of right iliac fossa pain . She was febrile and had guarding and rebound tenderness at the site of her pain” (50, p.73) “Eight months after hemicolectomy she presented again with a painful right iliac fossa mass” (50, p.73)	<ul style="list-style-type: none"> • Cancer treatment at first occurrence consisted of a right hemicolectomy, performed to remove the carcinoma • Cancer treatment at second occurrence included 5-fluorouracil and folinic acid • The patient passed away 12 months after second occurrence • Genetic analysis showed links between FAP, cancer, and IDs
Yang, Juang, Chuang, and Chou, 2000 (51)	Case report	Adult male 42 years	Low grade MALT thyroid lymphoma	Anterior chest discomfort	The patient “presented with the chief complaints of anterior chest discomfort and bilateral leg weakness of four to five months’ duration that was exacerbated in the previous week, and a right neck mass that he had had for several months.” (51, p.235)	<ul style="list-style-type: none"> • Treatment involved a total right thyroidectomy followed by conservative treatment with 20 mg of prednisolone each day due to the patient’s poor condition • There was no tumour recurrence or distant metastasis nine months later

<p>Sharaf El-Dean, Bakshi, and Giraldo, 2004 (52)</p>	<p>Case report</p>	<p>Adult male 26 years DS</p>	<p>Primary pericardial malignant mesothelioma (i.e. a cancer that began in heart tissue)</p>	<p>Right-sided chest pain</p>	<p>“Presented with a 2-week history of exertional shortness of breath, orthopnea, paroxysmal nocturnal dyspnea, and dry cough. He also had an episode of right-sided chest pain, which was aggravated by breathing.” (52, p. e107)</p>	<ul style="list-style-type: none"> • Cancer was not the initial diagnosis • Patient died a few days after hospitalization • Cancer discovered during autopsy • This form of cancer is not curable, 50% die within six months
<p>Hellebostad, Carpenter, Hasle, Mitchell, and Vyas, 2005 (53)</p>	<p>Case report with genetic analysis</p>	<p>Child female 3/6 years DS</p>	<p>AML age 3 ALL age 6</p>	<p>Bone pain</p>	<p>“She remained in complete continuous remission until aged 6 years, when she presented with bone pain” (53, p. 408)</p>	<ul style="list-style-type: none"> • Treated according to the NOPHO-AML93 protocol at the age of three • Treated at second occurrence according to the NOPHO-ALL92 protocol in the standard-risk group • Two years after treatment she was in continuous complete remission • Genetic analysis showed mutations in GATA1 exon 2 in the AML tissue sample but not in the ALL sample

Tuffrey- Wijne, Curfs, and Hollins, 2008 (15)	Case report with literature review (literature review section excluded)	Adult male 66 years Severe IDs	Lung cancer		“It was difficult for her [a palliative care nurse] to assess Pete’s needs and symptoms, because he often misunderstood her questions and did not clearly indicate his pain .” (15, p. 383) The patient “was given morphine to control his pain , but the carers were anxious about this. They weren’t sure when they could give him extra analgesia, or what they should do when Pete was too weak to swallow the medication.” (15, p. 383)	<ul style="list-style-type: none"> • No cancer treatment was given as the cancer was at an advanced stage due to late diagnosis • Palliative care provided for several months, several issues concerning emotional aspects and practicalities of his care are described
Hjorth, Vainer, Petersen, Larsen, and Hasle, 2010 (54)	Case report	Adult female 39 years DS	ALL Infiltrations of the liver, spleen, and dura mater	Abdominal pain	The patient was “admitted to the hospital because of abdominal pain and neck stiffness.” (55, p. e297)	<ul style="list-style-type: none"> • Supported in an intensive care unit but died 22 hours after admission • Diagnosis of leukaemia was not made until autopsy • This form of leukaemia is common in young children with DS but not in adults, therefore it was not suspected

Kaako and Kolade, 2010 (55)	Case report	Adult male 25 years Unspecified level and cause of IDs	Stage IV lung LCNEC (i.e. a cancer that began in the tissue lining the lung)	Back pain	<p>The patient “was brought by his caregiver with a chief complaint of low back pain for four months. The pain was located in his lower back and radiated to the right hip. Initially intermittent, the pain became constant, with gradual increase in severity to the point that the patient had refused to walk for three days before presentation. Pain was exacerbated by movement; no significant relief was attained with rest and/or analgesics.” (55, p.37)</p> <p>“On physical exam the patient was uncooperative, couched in a fetal position, tachycardic, hypertensive (154/94), and tender in the lumbar area” (55, p.37)</p> <p>“Back pain is a common complaint in the outpatient setting. In the absence of ‘red flags’ this is often benign non-specific pain. Red flags include neurological symptoms, duration exceeding one month, pain at rest or night time, history of cancer, unexplained weight loss and refractoriness to conservative therapy [60].” (55, p.38)</p>	<ul style="list-style-type: none"> • Caregiver had noticed that the patient was losing weight and had a poor appetite (i.e., mechanical symptoms) • No cancer treatment was given as the cancer was at an advanced stage due to late diagnosis • Palliative care provided for two weeks, at which point the patient developed pneumonia and died
-----------------------------	-------------	--	---	-----------	--	---

Kaako and
Kolade, 2010
(55)
(continued)

“Our patient presented with chronic lower back **pain** for more than four weeks, associated with poor appetite, weight loss, no improvement with bed rest, and lumbar tenderness. These findings were suggestive of an infectious or malignant spinal lesion.” (55, p.38)

“Diagnostic imaging studies are not recommended for nonspecific back **pain** in the first four-to-six weeks in the absence of ‘red flag symptoms’ [60]. In this particular case, in the context of [IDs], there was diagnostic delay and medical care was pursued four months after symptom onset. The diagnosis could have been made earlier if he had been evaluated for back **pain** soon after he reported it” (55, p. 38)

“This case of LCNEC is unique in its presentation as lower back **pain** in a non-smoking young male.” (49, p.38)

“In a series of 21 LCNECs, five were asymptomatic, six had chest **pain**, four exhibited cough or hemoptysis, and six

					had nonspecific presentations including flu-like symptoms, dyspnea and night sweats [61]" (55, p.38)	
Purvey, Hanna, Shaib, and Saif, 2010 (56)	Case report and literature review	Adult female 42 years	Metastatic pancreatic adeno-carcinoma	Abdominal pain	The patient "presented with two to three months history of weight loss up to 9 kg and epigastric abdominal pain " (56, p. 3) "A repeat CT scan after 5 months of therapy was performed due to worsening of abdominal pain and elevation of liver enzymes" (56, p. 3) "Unfortunately the patient developed further elevation of liver function tests and showed worsening of her abdominal pain ." (56, p. 3)	<ul style="list-style-type: none"> • Treated at first occurrence with gemcitabine 1,00mg/m² weekly for two weeks. • Treated at second occurrence with an endoscopic retrograde cholangiopancreatography • Due to significant hypotension the patient was not able to withstand the procedure and was therefore moved to an intensive care unit • Family decided to withdraw intubation "based on her co-morbid factors and extensive metastasis of pancreatic cancer" (56, p. 4)
		DS	(i.e. a cancer that began in the tissue lining the pancreas)			

Gil, Brett, Cordinhã, and Gomes, 2013 (57)	Case report	Child male 17 years TSC (i.e. a genetic neuro-cutaneous disorder, frequently coupled with IDs) Unspecified whether patient has IDs and of what level	Bilateral RCC (i.e. a cancer that began in the tissue lining the kidneys) Left kidney contained a clear cell RCC, Fuhrman grade three Right kidney contained a chromophobe RCC, with positive EMA	Lumbar and abdominal pain	The patient “was admitted to his local hospital in March 2012 with right lumbar pain . The pain had started 24 h prior to admission after a coughing bout and was described as a continuous pain that radiated to his right thigh.” (57, p.1) “On physical examination, he was found pale, had trouble walking and had symptoms of pain when pressure was applied to his right abdominal quadrant, which was tender on palpation but without rebound tenderness or rigidity.” (57, p. 1)	<ul style="list-style-type: none"> • Bilateral renal angiomyolipomas (i.e., common benign tumours found in TSC patients) were suspected at first • “Although malignancy could not be excluded as both lesions were highly vascularised” (57, p. 2) • A biopsy confirmed malignancy in the form of RCC, clear cell type, Fuhrman grade one (i.e., not advanced) • Treatment then involved a bilateral partial nephrectomy • Discovered of two different cancers, one in each kidney • Left kidney tumour found to be Fuhrman grade three • Patient remained clinically stable after surgery
--	-------------	--	---	---------------------------	--	---

<p>Satgé et al., 2013 (58)</p>	<p>Case report and literature review</p>	<p>Adult male 36 years Severe IDs due to varicella encephalitis at 18 months old</p>	<p>A muco- epidermoid carcinoma of the mandible (i.e. an oral cancer)</p>	<p>Un- specified due to level of IDs, but oral pain was presumed based on cancer location</p>	<p>“Difficulties in communicating pain or discomfort, condition for access to medical centers, ability to cooperate during care procedures, and the ability of care- givers to perform routine hygiene are key factors for oral health in [people with IDs].” (59, p. e22) After second surgery and insertion of a gastric tube, “There was no weight loss, and he seemed to accept the situation as long as the pain was controlled” (59, p. e23) “The San Salvador pain assessment scale was used and adapted for him because he could not make the usual facial movements as a result of his tumor and the surgical treatment” (59, p. e23)</p>	<ul style="list-style-type: none"> • First treatment involved a molar extraction and tumour resection • One month after surgery, diagnosis of a carcinoma was confirmed • Further treatment involved a right mandibular resection with cervical lymph node dissection • No radiotherapy or chemotherapy were administered due to the patient’s level of IDs • Local recurrence eight months after surgery, following this no further treatment administered • The patient died 20 months after initial discovery of the tumour
--	--	--	--	---	--	--

Roma et al., 2015 (59)	Case report	Adult female 23 years KS with mild to moderate IDs	Spinal ependymoma (i.e. tumour of the spine)	Acute lumbar pain	The patient “presented with intermittent tactile hypoesthesia of the feet and worsening lumbar pain ” (59, p. 2)	<ul style="list-style-type: none"> • Treatment involved an L3 to L5 laminotomy, with gross total resection of the tumour • Biopsy confirmed grade two cancer diagnosis • Patient remained in remission 14 months after diagnosis
------------------------------	----------------	---	---	-------------------------	---	---

Note. ALL = Acute Lymphoid Leukaemia. AML = Acute Myeloid Leukaemia. DS = Down syndrome. EMA = Endomysial Antibodies. FAP = Familial Adenomatous Polyposis. IDs = Intellectual Disabilities. KS = Kabuki Syndrome. LCNEC = Large Cell Neuroendocrine Carcinoma. MALT = Mucosa-Associated Lymphoid Type. NOPHO = Nordic society of Paediatric Haematology and Oncology. RCC = Renal Cell Carcinoma. TSC = Tuberous Sclerosis Complex.

Table 4

Respondents' methods for measuring (in grey) and treating cancer pain in people with intellectual disabilities (IDs). Frequency and percentages (%) for effectiveness of each method and phase in which treatment was applied only for respondents who had used each method (n = 63).

	Used? ^a (n=63)		In which phase of cancer development?				Effective?			
	Yes	No	Early	Advanced	Palliative	Does not apply	Yes	Somewhat	No	Does not apply
Individual pain behaviours/ knowing the patient	58 (92.06%)	5 (7.94%)	n/a	n/a	n/a	n/a	40 (68.97%)	17 (29.31%)	1 (1.72%)	0 (0.00%)
Using standard pain behaviour observation lists	42 (66.67%)	21 (33.33%)	n/a	n/a	n/a	n/a	13 (30.95%)	25 (59.52%)	4 (9.52%)	0 (0.00%)
Self-reports by patient	32 (50.79%)	31 (49.21%)	n/a	n/a	n/a	n/a	11 (34.38%)	19 (59.38%)	4 (12.50%)	0 (0.00%)
Other ^b	16 (25.40%)	47 (74.60%)	n/a	n/a	n/a	n/a	10 (62.50%)	6 (37.50%)	0 (0.00%)	0 (0.00%)
Strong opiates (e.g., morphine, methadone)	54 (85.71%)	9 (14.29%)	1 (1.85%)	14 (25.93%)	38 (70.37%)	1 (1.85%)	47 (87.04%)	6 (11.11%)	0 (0.00%)	0 (0.00%)
Acetaminophen/ Paracetamol	51 (80.95%)	12 (19.05%)	41 (80.39%)	7 (13.73%)	3 (5.88%)	0 (0.00%)	26 (50.98%)	22 (43.14%)	3 (5.88%)	0 (0.00%)
NSAIDs (e.g., Ibuprofen,	44	19	18	24	2	0	16	26	2	0

Cancer Pain in People with Intellectual Disabilities

Diclofenac, Naproxen)	(69.84%)	(30.16%)	(40.91%)	(54.55%)	(4.55%)	(0.00%)	(36.36%)	(59.09%)	(4.55%)	(0.00%)
Weak opiates (e.g., Codeine, Tramadol, Fentanyl)	44 (69.84%)	19 (30.16%)	2 (4.55%)	37 (84.09%)	5 (11.36%)	0 (0.00%)	26 (59.09%)	18 (40.91%)	0 (0.00%)	0 (0.00%)
Without medication ^c	40 (63.49%)	23 (36.51%)	14 (35.00%)	8 (20.00%)	12 (30.00%)	6 (15.00%)	16 (40.00%)	22 (55.00%)	0 (0.00%)	2 (5.00%)
Without medication ^d	38 (60.32%)	25 (39.68%)	20 (52.635)	8 (21.05%)	6 (15.79%)	4 (10.53%)	12 (31.58%)	24 (63.16%)	2 (5.26%)	0 (0.00%)
Without medication ^e	33 (52.38%)	30 (47.62%)	11 (33.33%)	10 (30.30%)	10 (30.30%)	2 (6.06%)	10 (30.30%)	21 (63.64%)	1 (3.03%)	1 (3.03%)
Medications for neuropathic pain	22 (34.92%)	41 (65.08%)	3 (13.64%)	13 (59.09%)	6 (27.27%)	0 (0.00%)	8 (36.36%)	13 (59.09%)	1 (4.55%)	0 (0.00%)
Other ^f	13 (20.63%)	50 (79.37%)	3 (23.08%)	2 (15.38%)	3 (23.08%)	5 (38.46%)	5 (38.46%)	2 (15.38%)	0 (0.00%)	6 (46.15%)

Note. Table ordered with most frequently used methods first. ^a = Multiple answers permitted. ^b = caregivers' reports, trial basis analgesia, and self-report facial scales.

^c= physiotherapy or aids (e.g., seat cushion, other mattress), ^d = distraction and/or reassurance, ^e = heat/cold, massage, and/or music. ^f = combinations of multiple treatments or emotion-oriented care, as well as responses explaining that the respondent is not a physician so did not employ any pain treatment.

Table 5

Recommendations from surveyed health care professionals with support from surrounding literature and future research suggestions to improve recognition, assessment, and treatment of cancer pain for people with intellectual disabilities (IDs).

	Recommendations from survey of health care professionals		Support for recommendations		Future research suggestions
	Broad	Specific	Present systematic review	Guidelines and research in surrounding fields	
Recognition	Caregivers are vital for noticing behavioural changes	Facilitate communication between all involved Possible pain signalling should be taken seriously Be aware of functional deterioration (e.g. people with IDs may continue work and hobbies despite pain)	Importance of behavioural signals due to communication issues in people with IDs (15,58) Only a few articles described the behavioural signs (50,55) Late cancer diagnosis can result from not acting on a patient's pain signalling 55)	<ul style="list-style-type: none"> • Observation of pain and discomfort related behaviours is recommended to recognise pain in the cognitively impaired, due to issues of communication (33,68) • Determination of pain behaviours universal for people with IDs is still not clear, so involvement of those who know the patient well is important to individualise pain observations (23,68) • Try to find a way to optimally communicate with the patient and those involved (62,72) • Atypical pain responses may be 	<ul style="list-style-type: none"> • Qualitative survey of people with IDs and cancer, as well as their family and carers. With the specific aim to understand how cancer pain is recognised and experienced. • Development of educational tools for families and caregivers of people with IDs about

				<p>misinterpreted as challenging behaviour or attributed to the person's IDs, such as self-injurious behaviour (66,67,76,77)</p> <ul style="list-style-type: none"> • "Ensuring that the person's baseline presentation is understood and recorded helps staff to identify if the person is experiencing pain." (71, p. 37) 	<p>pain as a symptom of cancer.</p>
Assessment/ measurement	Make extensive individualised pain signalling lists	Know about the patient's common pain behaviours and signals	Satgé and colleagues (68) individualised a pain assessment observation list to their patient	<ul style="list-style-type: none"> • Individualised approach advocated for pain management in people with IDs (32,67,71,75) • Create pain profiles in cooperation with patients, family, and caregivers. Save in electronic files and update (67,68) • Learn about the patient's past pain experiences (e.g. responses to pain, interventions and their effectiveness) as well as their comprehension of pain. Consider the patient's level of functioning, 	<ul style="list-style-type: none"> • Validation of practical tools for the individualised assessment of pain in people with IDs (e.g., 75). Tools should be applicable to the combination of acute and chronic pain states found in cancer and should be adaptable to individuals (32,67,73)


				communication abilities, physical and psychological health comorbidities (62,67)	
Assessment/ measurement	Conduct a thorough examination if pain is signalled or suspected	Examine for causes of pain Consider cancer on the list of possible diagnoses Examine under anaesthesia if the patient is continuously uncooperative	Cancer was not considered during the initial diagnosis stage in several articles (52,54)	<ul style="list-style-type: none"> Assume that what would bring you pain would also bring a patient with IDs pain (62) People with IDs can suffer the same “neurological, physiological, psychological and emotional consequences of pain” (68, p. e44). Overall deaths from cancer in the IDs population were not significantly different from the general population, despite the distribution of cancer sites being different. Therefore, cancer should be considered during diagnosis (78 	<ul style="list-style-type: none"> Awareness campaigns in hospitals and at General Practitioners that cancer should be considered in this population.
Treatment/ management	Use appropriate pain relief	Be aware that you may underestimate the level of pain, so consider both your	Difficulties with delivering morphine to a patient: when to give extra doses and how	<ul style="list-style-type: none"> Involve patient, family, and caregivers in the creation of an individualised pain management plan (62,67) 	<ul style="list-style-type: none"> Investigations into drug-to-drug interactions of medications for cancer,

and evaluate treatment outcome	pain level estimation from observation, the type of cancer, and the stage of cancer	to give it when the patient is unable to swallow (15)	<ul style="list-style-type: none"> Do not wait until the patient is in pain (act preventively), give medication according to a fixed schedule, adjusting dose to pain assessment (58) Consider polypharmacy, physical and psychological comorbidities, level of IDs, and possible differences in metabolism of analgesics (79), as well as the patient's desired outcomes and quality of life (67) Use the WHO analgesic pain ladder for chronic pain (67) It is useful to consult pharmacists, the Dutch palliative care guidelines for people with IDs (Bekkema 59), and online databases (e.g. https://about.medicinescomplete.com/) for known drug-to-drug interactions. 	pain, and pre-existing medications for comorbidities.
	See general population guidelines			
	Use trial analgesics			
	Communicate with the patient and family in assessment of pain to evaluate treatment outcome			

Treatment/ management	Treatment of pain should also include non- pharma- cological methods	Consider what the individual enjoys or what comforts them, as these activities or interventions could also relieve pain (see Table, Supplementary Digital Content 5: clinical situations 2 and 13) Consider what is best to improve the patient's quality of life. Increasing opiate doses may produce more side effects (see Table, Supplementary Digital Content 5: clinical situation 12)	A patient in palliative care was supported to do whatever he enjoyed in his last months, such as visiting a day centre he had always enjoyed (15)	<ul style="list-style-type: none"> • Involve the patient and those around them to individualise non-pharmacological pain treatments (67) • An integrated approach to cancer pain management would include non-invasive techniques (e.g., rehabilitative and psychological interventions), as well as anti-tumour (i.e. surgery) and pharmacological treatments (33) • Consider changing seating position, cushions, massage, physiotherapy, and heat/cold (67)
--------------------------	--	---	--	---



PRISMA 2009 Flow Diagram:



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

Online Table 1

Categories of pain descriptions in the literature in people with intellectual disabilities (IDs) who have cancer, from 11 eligible articles found in the systematic literature review. See note below for citations of corresponding article numbers.

Categories of pain description	Number of studies *	Case report	Adult	Child	Down syndrome	Other causes of IDs	Border-line IDs level	Mild IDs level	Moderate IDs level	Severe IDs level	IDs level unspecified	Carcinoma	Leukemia	Other form of cancer
Cancer pain in symptom presentation	9	1,2,3, 4,6,7, 8,9,1 1	1,2,3, 6,7,8, 11	4, 9	2,3,4,6,8	1 (i.e., FAP) 7 (cause unspecified) 9 (i.e., TSC) 11 (i.e., KS)	1	11	11	0	2,3,4,6, 7,8,9	1,7,8,9	4,6	2 (i.e., thyroid lymphoma) 3 (i.e., pericardial mesothelioma) 11 (i.e., Spinal ependymoma)
Cancer pain communication	5	1, 5,7, 9, 10	1,5,7, 10	9	0	1 (i.e., FAP) 5 (cause unspecified) 7 (cause unspecified) 9 (i.e., TSC) 10 (i.e., varicella encephalitis)	1	0	0	5,10	7,9	1,7,9,10	0	5 (i.e., lung cancer)
Cancer pain assessment and treatment	2	5,10	5,10	0	0	5 (cause unspecified) 10 (i.e., varicella encephalitis)	0	0	0	5,10	0	10	0	5 (i.e., lung cancer)

Note. *Articles may contain multiple categories of pain descriptions. Most commonly addressed category is presented first.

Article number: 1) Koorey et al., 2000; 2) Yang et al., 2000; 3) Sharaf El-Dean et al., 2004; 4) Hellebostad et al., 2005; 5) Tuffrey-Wijne et al., 2008; 6) Hjorth et al., 2010; 7) Kaako & Kolade, 2010; 8) Purvey et al., 2010; 9) Gil et al., 2013; 10) Satgé et al., 2013; 11) Roma et al., 2015.

FAP = Familial Adenomatous Polyposis. KS = Kabuki Syndrome. TSC = Tuberous Sclerosis Complex.

Online Table 2

Respondents' occupation and level of experience with cancer in people with intellectual disabilities (IDs) (N=102).

		How often have you been involved with cancer in people with IDs?				Total	Percentage of total respondents	Total with experience
		Never	A few times	Several times	Often			
What is your occupation?	Physician for people with IDs	1 (3.6%)	15 (53.6%)	12 (42.9%)	0 (0%)	28 (100%)	(27.5%)	27 (42.9%)
	Behavioural expert	8 (42.1%)	8 (42.1%)	3 (15.8%)	0 (0%)	19 (100%)	(18.6%)	11 (17.5%)
	Dentist	18 (94.7%)	1 (5.3%)	0 (0%)	0 (0%)	19 (100%)	(18.6%)	1 (1.6%)
	Nurse or nurse specialist	2 (22.2%)	3 (33.3%)	3 (33.3%)	1 (11.7%)	9 (100%)	(8.8%)	7 (11.1%)
	Other occupation	4 (44.4%)	2 (22.2%)	3 (33.3%)	0 (0%)	9 (100%)	(8.8%)	5 (7.9%)
	Mentor	0 (0%)	5 (71.4%)	2 (28.6%)	0 (0%)	7 (100%)	(6.9%)	7 (11.1%)
	General practitioner	4 (57.1%)	2 (28.6%)	1 (14.3%)	0 (0%)	7 (100%)	(6.9%)	3 (4.8%)
	Palliative care consultant	0 (0%)	0 (0%)	2 (100%)	0 (0%)	2 (100%)	(2%)	2 (3.2%)
	Physio-therapist	2 (100%)	0 (0%)	0 (0%)	0 (0%)	2 (100%)	(2%)	0 (0%)
	Oncologist	N/A N/A	N/A N/A	N/A N/A	N/A N/A	0 N/A	(0%)	0 (0%)
Total		39 (38.2%)	36 (35.3%)	26 (25.5%)	1 (1%)	102 (100%)	(100%)	63 (61.8%)

Note. Table ordered on percentage of total respondents, followed by percentage of total respondents involved with cancer in people with IDs. No oncologists completed the survey. The 'other' response included speech therapist, basic physician, physician's assistant, physician (previously general practitioner), services coordinator, dental hygienist, cluster manager, and a policy maker who is an acquaintance of a person with cancer and IDs.

Online Table 3

Challenges regarding cancer pain in people with intellectual disabilities (IDs), with notable examples specified by respondents. Frequency and percentage (%) of responses displayed in order of commonality, with most frequent or notable solutions posed by health care professionals displayed (n=63).

Challenges experienced	Yes	No	Suggested solutions
Communication/cooperation with the patient	58 (92.06%)	5 (7.94%)	If a patient shows anxiety and incomprehension: coordinate communication with specialised caregiver
Pain signalling (e.g., inability to communicate, anxiety, subjective or ambiguous behaviour)	55 (87.30%)	8 (12.70%)	Example given of a patient who walks with broken leg due to autism: check abnormal posture or behaviour
Medical complexity of the target group	49 (77.78%)	14 (22.22%)	Education, multidisciplinary cooperation, use multiple protocols, check drug-to-drug interactions, consult specialists
Pain assessment (e.g., lack of validated tools, lack of objective measurement, distinction from anxiety/fear)	48 (76.19%)	15 (23.81%)	Create individual pain profiles, check comprehension of rating scales
Lack of research	41 (65.08%)	22 (34.92%)	Case studies, practice-based, long-term medication, specific syndromes
Pain treatment (e.g., unable to evaluate effectiveness, family involvement, uncooperative behaviour, comorbidities)	40 (63.49%)	23 (36.51%)	Distraction, evaluate treatment effectiveness, check drug-to-drug interactions
Communication/collaboration with other health care workers	35 (55.56%)	28 (44.44%)	Frequent team evaluation about shared patient file, check cushions/shoes before increasing pain medication
Knowledge about differences between tumour profiles and prevalence of cancers in different genetic syndromes	35 (55.56%)	28 (44.44%)	Search for information on tumour profiles, treat pain is a separate symptom, provide further scientific research, education, and clinical lessons
Communication/collaboration with the patient's family	30 (47.62%)	33 (52.38%)	Involve family early and frequently: design pain signalling plan
Lack of a clear national guidelines for cancer pain in people with IDs	24 (38.10%)	39 (61.90%)	This doesn't hinder treatment, would be beneficial to specify guidelines for people with IDs
Other knowledge about cancer in people IDs (e.g., fear, reactions to medications, laws)	24 (38.10%)	39 (61.90%)	Use palliative care specialists and a biopsychological model, increase awareness in health care specialists
Lack of (inter)national conferences/symposiums	22 (34.92%)	41 (65.08%)	Ask what the needs are, organize symposium
Knowledge of existing national guidelines	20 (31.75%)	43 (68.25%)	Update and distribute guidelines, clinical lessons, use experts
Lack of (inter)national taskforces	20 (31.75%)	43 (68.25%)	Increase interest, Dutch palliative taskforce is almost set up
Other (e.g., giving the patient more knowledge on cancer pain, anxiety reduction, increase awareness of pain)	5 (7.94)	58 (92.06%)	Adapt information for people with IDs, mentors/caregivers should accompany patient to physician

Online Table 4

Additional challenges and anonymous clinical examples experienced by health care professionals. Responses translated from Dutch by first and second authors, S.K. Millard and N.C. De Knegt.

Challenge or Clinical situation	Outcome and suggested solution
1) Patient with mild [IDs] and autism with gastric carcinoma, in addition to pain also had vomiting symptoms. She was always afraid that she would have to go to the hospital if she indicated complaints (such as pain). This made it difficult to assess whether she had (pain) complaints.	Solution was to have very frequent contact during visits of nurse and doctor, for just a chat / weighing etc. and clinical assessment. Giving explanation on her level, why she has pain. Patient involved in this by, for example, making VAS with faces for her. In terms of pain treatment I was fine with existing guidelines
2) Male, 50 years old, severe IDs and colon carcinoma with metastasis. Discovered by severe anaemia. Pain relief with fentanyl seemed inadequate.	Attention was spent on the things that this man always did and liked. Pain relief was adapted to his daily rhythm: pain relief before an activity or care moment restored the daily rhythm, with a beneficial effect on the overall well-being. The last weeks were spent on things that improved quality of life for this man (for example car trips with his brother and sister).
3) Patient with Down syndrome is deteriorating, health care professional suspect dementia, but mentor indicates that it is something else. She sees this in small signs of pain.	Patient appears to have a brain tumour. He gets medication against the pain and finally comes to rest to pass away.
4) Mature man who cannot speak and is always in good health, eats worse, stands bent over, and has blood in faeces. He doesn't tolerate physical examination. This is only possible under anaesthesia, but parents refuse.	After a few months of muddling, a MRI is done under anaesthesia, in which oesophageal cancer is diagnosed. The man lives a few weeks with efficient pain medication in a pleasant atmosphere of warm care and dies peacefully.
5) Patient was in an advanced stage of oesophageal cancer but indicated that he had no pain. Pain meant for him that he would receive medication and according to him, his mother had died from medication use.	Family saw that he had a lot of pain but the doctor only wanted to take action if the patient reported pain. Pain relief was delayed for months, which was a heavy last period for the patient. The family and supervisors should have taken symptoms more seriously.
6) Cancer is usually only discovered at a late stage, such as a testicular carcinoma in a man with Down syndrome and dementia who didn't want to be examined or touched. Severe behavioural problems that increased in the last months and were recognised as pain, for which he received paracetamol. Dental examination under anaesthesia revealed testicular carcinoma with peritonitis carcinomas.	Detection could have been earlier if there had been a general physical examination under anaesthesia. This could have been combined with a dental examination.
7) As a team we had a patient with mild IDs who communicated pain signals. Due too little knowledge about her pain behaviours and pain behaviours in mild IDs in general, we could not reveal the cause. GP sent her back several times with simple pain relief. After a few months and at the urging of us as a team due to our 'gut feeling', she was eventually examined and diagnosed with cancer. Patient dies after a very short and intense sickbed.	What we needed and certainly would have helped, was more knowledge about her pain behaviours, pain history, better communication with family / legal representatives and general practitioner, and taking our 'gut feeling' seriously.

Online Table 4: continued

Challenge or Clinical Situation	Solution
8) Caregiver of patient feels alarmed due to weight loss, less eating, less activity, changes in the face and posture. Tumours are detected during medical examination.	Extensive individual pain signalling list is made and acted on it. Patient eats better and is more active.
9) The routine of daily life can be so important for patients that pain is ignored. A man with metastatic bone cancer went to work every day and just danced the night before his death: it didn't go that well anymore, but he found peace in the daily routine.	Be aware of functional deterioration such as changes during work activities and hobbies.
10) Patient with brain tumour who displays self-injury, but has always done this. Pain is not clear, caregivers are divided in what to do.	Pain relief is given on trial and is effective.
11) An older man who spoke a few words had a suddenly deteriorating mood. He looked gloomy and angry, but did everything else and had in the first instance no physical complaints. No abnormalities were shown in blood tests, so he was treated for depression. The adjustments only slightly improved his mood. Further physical examination showed metastatic cancer, which must have been painful.	It would be useful if a more thorough physical screening could be done (especially also for cancer).
12) Patient has metastatic gastric carcinoma. Wears a fentanyl patch. Has a vasovagal reaction when he gets out of bed, so remains in bed. Gets pressure sores. He clearly states by means of the VAS score that he has pain (in his heels). Fentanyl patch dose was increased. Resulted in allodynia: he screamed from the pain while we only looked at his legs. Further increase in Fentanyl patch dose caused severe breathing depressions and delirium.	You would normally not give extra morphine for pressure sores (unless they are real decubitus ulcers). Patient already reacted strongly to the fentanyl. Such things happen due to a lack of background knowledge about pain relief and how you assess a patient.
13) Female, multiple disabilities (low intellectual level), autistic behaviour, could not talk in complete sentences, sleeps at home under a heavy blanket for a feeling of safety. Has leukaemia: showed visible pain, shivered constantly, and said "ouch". She could not cope with the pain due to tiredness because she slept badly.	I put four blankets from the hospital on her. She became visibly calm, her face showed a more satisfying expression. When we brought her own blanket, she slept better and the pain medication was more effective. She stopped shivering with pain.

Note. IDs = Intellectual Disabilities. VAS = Visual Analogue Scale.